| scholarly article | Q13442814 |
| P356 | DOI | 10.1530/JME-12-0007 |
| P8608 | Fatcat ID | release_csesewz6irggbnewrjlwbttbiu |
| P3181 | OpenCitations bibliographic resource ID | 2891758 |
| P698 | PubMed publication ID | 22355097 |
| P50 | author | Vuk Stambolic | Q54269849 |
| Saroj Niraula | Q60596964 | ||
| P2093 | author name string | P. J. Goodwin | |
| R. J. O. Dowling | |||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | metformin | Q19484 |
| P304 | page(s) | R31-43 | |
| P577 | publication date | 2012-06-01 | |
| P1433 | published in | Journal of Molecular Endocrinology | Q15716709 |
| P1476 | title | Metformin in cancer: translational challenges | |
| P478 | volume | 48 |
| Q53233111 | A pharmacist's perspective on metformin use and cancer outcomes |
| Q47240106 | A reappraisal on metformin |
| Q38796334 | A review for clinicians: Prostate cancer and the antineoplastic properties of metformin |
| Q37105231 | A twenty-first century cancer epidemic caused by obesity: the involvement of insulin, diabetes, and insulin-like growth factors |
| Q55401962 | Actionable Metabolic Pathways in Heart Failure and Cancer—Lessons From Cancer Cell Metabolism. |
| Q26826123 | Adipose tissue and adipocytes support tumorigenesis and metastasis |
| Q53177190 | Anti-Diabetic Drugs: Cure or Risk Factors for Cancer? |
| Q28080170 | Anti-tumor activity of metformin: from metabolic and epigenetic perspectives |
| Q47790169 | Antidiabetic medication, statins and the risk of endometrioid endometrial cancer in patients with type 2 diabetes |
| Q46360731 | Association of Metformin Use and Survival Outcome in Women With Cervical Cancer |
| Q37588301 | Biguanides sensitize leukemia cells to ABT-737-induced apoptosis by inhibiting mitochondrial electron transport |
| Q34258945 | Calorie restriction and cancer prevention: a mechanistic perspective |
| Q47638080 | Cause-specific mortality in endometrioid endometrial cancer patients with type 2 diabetes using metformin or other types of antidiabetic medication |
| Q57133081 | Chemoprevention of breast cancer |
| Q38121736 | Clinical management of obese patients with cancer |
| Q37676300 | Combining metformin and nelfinavir exhibits synergistic effects against the growth of human cervical cancer cells and xenograft in nude mice |
| Q46976979 | Cryptotanshinone induces G1 cell cycle arrest and autophagic cell death by activating the AMP-activated protein kinase signal pathway in HepG2 hepatoma |
| Q30662689 | Current phase II clinical data for ridaforolimus in cancer |
| Q33591379 | Diabetic concentrations of metformin inhibit platelet-mediated ovarian cancer cell progression |
| Q26774911 | Dietary Restriction and Nutrient Balance in Aging |
| Q37299288 | Dietary restriction-resistant human tumors harboring the PIK3CA-activating mutation H1047R are sensitive to metformin |
| Q88782225 | Differences in cancer survival among white and black cancer patients by presence of diabetes mellitus: Estimations based on SEER-Medicare-linked data resource |
| Q33675285 | Direct effects of metformin in the endometrium: a hypothetical mechanism for the treatment of women with PCOS and endometrial carcinoma. |
| Q37171068 | Disruption of insulin receptor function inhibits proliferation in endocrine-resistant breast cancer cells |
| Q38687543 | Does Metformin Reduce Cancer Risks? Methodologic Considerations |
| Q58768079 | Effect of metformin on the survival of patients with ALL who express high levels of the ABCB1 drug resistance gene |
| Q36047450 | Effect of metformin vs placebo on and metabolic factors in NCIC CTG MA.32. |
| Q39043221 | Effects of metformin on breast cancer cell proliferation, the AMPK pathway and the cell cycle |
| Q33702357 | Effects of prolonged exposure to low dose metformin in thyroid cancer cell lines. |
| Q37437550 | Enhanced anti-tumor activity and cytotoxic effect on cancer stem cell population of metformin-butyrate compared with metformin HCl in breast cancer |
| Q28391921 | Epithelial cancers in the post-genomic era: should we reconsider our lifestyle? |
| Q85217506 | FASNating targets of metformin in breast cancer stem-like cells |
| Q33693626 | Formalizing an integrative, multidisciplinary cancer therapy discovery workflow |
| Q47357171 | Friend or foe? Mitochondria as a pharmacological target in cancer treatment |
| Q38758637 | Glucose Promotes a Pro-Oxidant and Pro-Inflammatory Stromal Microenvironment Which Favors Motile Properties in Breast Tumor Cells. |
| Q37525828 | Glucose promotes breast cancer aggression and reduces metformin efficacy. |
| Q55472178 | High Accumulation of Metformin in Colonic Tissue of Subjects With Diabetes or the Metabolic Syndrome. |
| Q39040854 | Hyperglycaemia Induced by Novel Anticancer Agents: An Undesirable Complication or a Potential Therapeutic Opportunity? |
| Q36414231 | Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer |
| Q64051933 | Identifying the murine mammary cell target of metformin exposure |
| Q51072153 | Impact of Diabetes, Insulin, and Metformin Use on the Outcome of Patients With Human Epidermal Growth Factor Receptor 2-Positive Primary Breast Cancer: Analysis From the ALTTO Phase III Randomized Trial. |
| Q36417868 | Insulin Therapy and Cancer in Type 2 Diabetes |
| Q38193208 | Insulin-like growth factor-II: its role in metabolic and endocrine disease |
| Q58696780 | Integrated Pharmacodynamic Analysis Identifies Two Metabolic Adaption Pathways to Metformin in Breast Cancer |
| Q36905125 | Investigating and targeting chronic lymphocytic leukemia metabolism with the human immunodeficiency virus protease inhibitor ritonavir and metformin |
| Q36630561 | LKB1 inactivation dictates therapeutic response of non-small cell lung cancer to the metabolism drug phenformin |
| Q90431016 | Long-term outcomes of progestin plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer patients |
| Q26775379 | Management of hyperglycemia from epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) targeting T790M-mediated resistance |
| Q38819985 | Mechanism of metformin action in MCF-7 and MDA-MB-231 human breast cancer cells involves oxidative stress generation, DNA damage, and transforming growth factor β1 induction. |
| Q34283475 | Mechanism of metformin-dependent inhibition of mammalian target of rapamycin (mTOR) and Ras activity in pancreatic cancer: role of specificity protein (Sp) transcription factors |
| Q49908128 | Mechanisms Linking Obesity and Thyroid Cancer Development and Progression in Mouse Models |
| Q88720563 | Metabolic changes in bladder cancer |
| Q47101870 | Metabolic modulation of Ewing sarcoma cells inhibits tumor growth and stem cell properties |
| Q48018091 | Metformin Alleviated the Neuronal Oxidative Stress in Hippocampus of Rats under Single Prolonged Stress |
| Q61797808 | Metformin Counteracts HCC Progression and Metastasis Enhancing KLF6/p21 Expression and Downregulating the IGF Axis |
| Q35751116 | Metformin Induces Apoptosis and Downregulates Pyruvate Kinase M2 in Breast Cancer Cells Only When Grown in Nutrient-Poor Conditions |
| Q27348974 | Metformin Reduces Desmoplasia in Pancreatic Cancer by Reprogramming Stellate Cells and Tumor-Associated Macrophages |
| Q60919666 | Metformin Results in Diametrically Opposed Effects by Targeting Non-Stem Cancer Cells but Protecting Cancer Stem Cells in Head and Neck Squamous Cell Carcinoma |
| Q88747151 | Metformin Targets Glucose Metabolism in Triple Negative Breast Cancer |
| Q34357389 | Metformin and breast cancer risk: a meta-analysis and critical literature review |
| Q33971668 | Metformin and phenformin deplete tricarboxylic acid cycle and glycolytic intermediates during cell transformation and NTPs in cancer stem cells |
| Q44478489 | Metformin and the thyroid: some questions still remain |
| Q28538155 | Metformin as an adjuvant drug against pediatric sarcomas: hypoxia limits therapeutic effects of the drug |
| Q28074225 | Metformin as an adjuvant treatment for cancer: a systematic review and meta-analysis |
| Q50001260 | Metformin as an anti-cancer agent: actions and mechanisms targeting cancer stem cells. |
| Q37313880 | Metformin displays in vitro and in vivo antitumor effect against osteosarcoma |
| Q33683560 | Metformin disrupts malignant behavior of oral squamous cell carcinoma via a novel signaling involving Late SV40 factor/Aurora-A. |
| Q55262517 | Metformin exerts antitumor activity via induction of multiple death pathways in tumor cells and activation of a protective immune response. |
| Q39290525 | Metformin in Lung Cancer: Review of in Vitro and in Vivo Animal Studies |
| Q64105328 | Metformin induces the AP-1 transcription factor network in normal dermal fibroblasts |
| Q36532994 | Metformin inhibition of mTORC1 activation, DNA synthesis and proliferation in pancreatic cancer cells: Dependence on glucose concentration and role of AMPK |
| Q37648017 | Metformin inhibits androgen-induced IGF-IR up-regulation in prostate cancer cells by disrupting membrane-initiated androgen signaling |
| Q36896122 | Metformin inhibits growth and enhances radiation response of non-small cell lung cancer (NSCLC) through ATM and AMPK |
| Q33597162 | Metformin inhibits mitochondrial complex I of cancer cells to reduce tumorigenesis |
| Q37570847 | Metformin inhibits skin tumor promotion in overweight and obese mice |
| Q39312255 | Metformin is synthetically lethal with glucose withdrawal in cancer cells. |
| Q64061793 | Metformin prevention of doxorubicin resistance in MCF-7 and MDA-MB-231 involves oxidative stress generation and modulation of cell adaptation genes |
| Q37352852 | Metformin sensitizes the response of oral squamous cell carcinoma to cisplatin treatment through inhibition of NF-κB/HIF-1α signal axis |
| Q53378831 | Metformin synergizes 5-fluorouracil, epirubicin, and cyclophosphamide (FEC) combination therapy through impairing intracellular ATP production and DNA repair in breast cancer stem cells. |
| Q58790135 | Metformin, an Anti-diabetic Drug to Target Leukemia |
| Q39247550 | Metformin-associated lactic acidosis (MALA): Moving towards a new paradigm. |
| Q36062114 | Metformin-induced killing of triple-negative breast cancer cells is mediated by reduction in fatty acid synthase via miRNA-193b |
| Q42700292 | Metformin: A Bridge between Diabetes and Prostate Cancer. |
| Q94603091 | Metformin: A Possible Option in Cancer Chemotherapy |
| Q37608817 | Metformin: On Ongoing Journey across Diabetes, Cancer Therapy and Prevention |
| Q41545473 | Metformin: a review of its potential indications |
| Q43576506 | Metformin: an old drug with new potential |
| Q36454552 | Minireview: The Year in Obesity and Cancer |
| Q36506529 | Mitochondrial Porin Por1 and Its Homolog Por2 Contribute to the Positive Control of Snf1 Protein Kinase in Saccharomyces cerevisiae |
| Q27852608 | Molecular determinants of outcome with mammalian target of rapamycin inhibition in endometrial cancer |
| Q37478905 | Molecular pathways: adipose inflammation as a mediator of obesity-associated cancer. |
| Q37733377 | New insight for metformin against bladder cancer |
| Q36759129 | Obesity and Cancer: An Angiogenic and Inflammatory Link |
| Q35817986 | Obesity and Diabetes: The Increased Risk of Cancer and Cancer-Related Mortality |
| Q34305020 | Obesity and cancer risk: evidence, mechanisms, and recommendations |
| Q37200502 | Obesity, diabetes, and survival outcomes in a large cohort of early-stage breast cancer patients |
| Q37276139 | Obesity, metabolism and the microenvironment: Links to cancer |
| Q64890350 | Observational Studies on the Association Between Post-diagnostic Metformin Use and Survival in Ovarian Cancer: A Systematic Review and Meta-Analysis. |
| Q27010558 | Old drug, new trick: repurposing metformin for gynecologic cancers? |
| Q53273805 | Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer. |
| Q38097730 | Postmenopausal breast cancer, androgens, and aromatase inhibitors. |
| Q36250770 | Promising clinical practices of metformin in women with PCOS and early-stage endometrial cancer. |
| Q87352669 | Proposal for the modification of metformin use in patients with chronic kidney disease |
| Q28075971 | ROS homeostasis and metabolism: a dangerous liason in cancer cells |
| Q41083568 | Recent advances in the use of metformin: can treating diabetes prevent breast cancer? |
| Q35145204 | Reduction behavior induced by HL010183, a metformin derivative against the growth of cutaneous squamous cell carcinoma |
| Q37448089 | Regulation of metformin response by breast cancer associated gene 2. |
| Q38185970 | Repositioning metformin in cancer: genetics, drug targets, and new ways of delivery |
| Q64098059 | Repurposed Biguanide Drugs in Glioblastoma Exert Antiproliferative Effects via the Inhibition of Intracellular Chloride Channel 1 Activity |
| Q38637111 | Results from 11C-metformin-PET scans, tissue analysis and cellular drug-sensitivity assays questions the view that biguanides affects tumor respiration directly. |
| Q29247988 | Role of Nrf2 and protective effects of Metformin against tobacco smoke-induced cerebrovascular toxicity |
| Q35035126 | Sorafenib synergizes with metformin in NSCLC through AMPK pathway activation |
| Q57073543 | Subversion of Systemic Glucose Metabolism as a Mechanism to Support the Growth of Leukemia Cells |
| Q35116609 | Suppression of the HSF1-mediated proteotoxic stress response by the metabolic stress sensor AMPK |
| Q40950693 | Synergistic Benefit of Statin and Metformin in Gastrointestinal Malignancies |
| Q38736840 | Synergistic cell death in FLT3-ITD positive acute myeloid leukemia by combined treatment with metformin and 6-benzylthioinosine |
| Q26801412 | Targeting LKB1 in cancer - exposing and exploiting vulnerabilities |
| Q27027219 | Targeting mitochondria metabolism for cancer therapy |
| Q64106969 | The Allele of rs11212617 Associates With Higher Pathological Complete Remission Rate in Breast Cancer Patients Treated With Neoadjuvant Metformin |
| Q41242882 | The Clinical Effect of Metformin on the Survival of Lung Cancer Patients with Diabetes: A Comprehensive Systematic Review and Meta-analysis of Retrospective Studies |
| Q92281751 | The Effect of Metformin on Mortality Among Diabetic Cancer Patients: A Systematic Review and Meta-analysis |
| Q55114306 | The Oncojanus Paradigm of Respiratory Complex I. |
| Q33893949 | The Repurposing Drugs in Oncology (ReDO) Project. |
| Q35609517 | The Role of the Insulin/IGF System in Cancer: Lessons Learned from Clinical Trials and the Energy Balance-Cancer Link |
| Q36477885 | The Use of Metformin and the Incidence of Lung Cancer in Patients With Type 2 Diabetes |
| Q94545901 | The cytotoxicity of gallium maltolate in glioblastoma cells is enhanced by metformin through combined action on mitochondrial complex 1 |
| Q35000522 | The effect of metformin on breast cancer outcomes in patients with type 2 diabetes |
| Q64252594 | The effect of metformin therapy on incidence and prognosis in prostate cancer: A systematic review and meta-analysis |
| Q38728567 | The expanding role of metformin in cancer: an update on antitumor mechanisms and clinical development |
| Q36742179 | The impact of metformin and salinomycin on transforming growth factor β-induced epithelial-to-mesenchymal transition in non-small cell lung cancer cell lines |
| Q37626493 | The interplay of AMP-activated protein kinase and androgen receptor in prostate cancer cells |
| Q35761723 | Therapeutic Concentrations of Metformin: A Systematic Review |
| Q26783569 | Therapeutic options for management of endometrial hyperplasia |
| Q26800890 | Treatment Strategies that Enhance the Efficacy and Selectivity of Mitochondria-Targeted Anticancer Agents |
| Q38148147 | Unravelling the connection between metabolism and tumorigenesis through studies of the liver kinase B1 tumour suppressor |
| Q35466765 | Use of noninsulin anti diabetics for prevention and treatment of cancer- narrative review article |
| Q24745996 | Validating drug repurposing signals using electronic health records: a case study of metformin associated with reduced cancer mortality |
| Q44978696 | Which anti-tumour benefits to be expected from metformin? |
Search more.